Home / Companies / Cartesian Therapeutics, Inc. / 14 Jun 2024
Cartesian Therapeutics, Inc.: meeting of 14 Jun 2024
Votes reported on Form N-PX, item by item
117 Form N-PX filers reported votes at the Cartesian Therapeutics, Inc. meeting of 14 Jun 2024. Their records fall into 4 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.
foragainstabstain, withhold or otheramber tick: the portion cast against management
Items
DIRECTOR ELECTIONSIssuer
Director elections
2 nominees; 73.3% of reported votes for; 30 filers withheld from or voted against at least one nominee.
176 vote records from 47 filers. 0 of the 47 filers that marked the item either way voted against management.
SECTION 14A SAY-ON-PAY VOTESIssuer
Advisory vote on executive pay (say-on-pay)
177 vote records from 118 filers. 84 of the 114 filers that marked the item either way voted against management. 4 filers reported this item without a management mark.
AUDIT-RELATEDIssuer
Audit-related items (auditor ratification)
88 vote records from 47 filers. 0 of the 47 filers that marked the item either way voted against management.
COMPENSATIONIssuer
COMPENSATION: management items
Management items in this category are shown together; filers word and number them differently.
88 vote records from 47 filers. 46 of the 47 filers that marked the item either way voted against management.
How the largest families voted
| Family | 1. Directors | 2. Say-on-pay | 3. Auditor |
|---|---|---|---|
| Vanguard | Split or no vote | For | For |
| BlackRock and iShares | For | Against * | For |
| Fidelity | For | For | For |
| State Street and SPDR | Split or no vote | For | For |
| Invesco | For | Against * | For |
| Equitable | For | Against * | For |
| Charles Schwab | For | Against * | For |
| Nuveen and TIAA | Split or no vote | Against * | For |
| ProShares and ProFunds | Split or no vote | Against * | For |
| Morgan Stanley, Eaton Vance and Calvert | For | Against * | For |
| J.P. Morgan | For | Against * | For |
| Goldman Sachs | No report | For | No report |
| PGIM and Prudential | No report | Against * | No report |
| Northern Trust and FlexShares | For | For | For |
| T. Rowe Price | For | Against * | For |
| Lincoln Financial | For | For | For |
| Voya | Split or no vote | Against * | For |
| Nationwide | Split or no vote | Against * | For |
| Victory Capital | Split or no vote | Against * | For |
| Guggenheim and Rydex | Split or no vote | Against * | For |
| Columbia Threadneedle | No report | Against * | No report |
| BNY Mellon | No report | For | No report |
| Principal | Split or no vote | Against * | For |
| Pacific Life funds | For | Against * | For |
| AllianceBernstein | No report | Against * | No report |
| DWS | Split or no vote | Against * | For |
| Janus Henderson | No report | Against * | No report |
* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.
Questions
How did large funds vote at the Cartesian Therapeutics, Inc. meeting?
117 Form N-PX filers reported votes at the meeting of 14 Jun 2024. On say-on-pay, 84 of 114 voted against management (73.7%). The family table lists each of the largest families item by item.
Is this the meeting result?
No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Cartesian Therapeutics, Inc. on Form 8-K.
Why are director elections shown as counts only?
Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.
Every meeting on file for Cartesian Therapeutics, Inc.
Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Cartesian Therapeutics, Inc. with a meeting date within three days of 14 Jun 2024. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.